Fellows’ Journal Club Editor’s Comment These authors retrospectively evaluated 12 patients with natalizumab–progressive multifocal leukoencephalopathy (PML), 5 with PML from other causes, and 55 patients with MS without progressive PML for comparison. They observed T2* or SWI signal abnormalities at